
ESCAPE Bio: A preclinical biopharmaceutical company developing therapies for neurodegenerative diseases.
Founded with a mission to address genetically defined neurodegenerative diseases, ESCAPE Bio is a preclinical stage biopharmaceutical company. The organization is dedicated to discovering and developing innovative therapies aimed at treating central nervous system (CNS) disorders. By focusing on genetic underpinnings, ESCAPE Bio aims to make a significant clinical impact for patients suffering from these debilitating conditions.
Notable figures associated with ESCAPE Bio include experienced scientists and industry leaders in the field of neurodegeneration. The company has garnered attention and support from prominent investors in the biotech sector. Key achievements include advancing multiple therapeutic candidates through preclinical development stages, positioning the company as a promising player in the fight against CNS diseases. ESCAPE Bio's work holds the potential to transform treatment paradigms and improve patient outcomes significantly.

Denali Therapeutics

CuraSen Therapeutics
curasen.com

Convalesce
convalesce.co

Engrail Therapeutics
engrail.com

Capsida Biotherapeutics
capsida.com

Novoron Bioscience
novoron.com

Chase Therapeutics

Cogent Biosciences
cogentbio.com

Spinogenix
spinogenix.com

Enterin
enterininc.com

Apic Bio

Faze Medicines
fazemed.com

Therini Bio
therinibio.com

Amplifica
amplificabio.com

VistaGen Therapeutics
Companies similar to Escape Bio include Denali Therapeutics, CuraSen Therapeutics, Convalesce and Engrail Therapeutics.
Escape Bio was founded in 2015.
Escape Bio's headquarters is located in South San Francisco, CA, US.
Escape Bio's most recent funding round was for $73M (USD) in September 2020.
As of Sep 14, 2020, Escape Bio has raised a total of $187.1M (USD).
Escape Bio has 39 employees as of Feb 5, 2024.